CLEVELAND, Aug. 3, 2017 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today highlights from the 2017 Annual
The company's MRIdian® System was the focus of 30 abstracts selected by AAPM including several talks describing the significant advantages of daily on-table adaptive radiation therapy and its positive clinical impact on treatment. MR-guided on-table adaptive therapy, which is currently possible only with the MRIdian System, allows for dose escalation for SBRT treatments and dose de-escalation in cases where the critical structures are too close to the tumor.
The AAPM Scientific Session talks also highlighted MRIdian's fully integrated workflow for adaptive therapy, which incorporates complete Monte Carlo dose replanning to account for changes in the shape and position of the tumor and adjacent organs in less than two minutes. More than 2,000 on-table adaptive fractions have been delivered using the MRIdian System, attesting to its growing adoption and clinical value.
ViewRay featured a number of presentations in the company's booth given by MRIdian users from five top cancer centers: Henry Ford Health System in Metro Detroit; University of California, Los Angeles; Washington University in St. Louis; University of Wisconsin; and University of Miami. Below are highlights from these talks:
To watch video recaps from some of the in-booth MRIdian user presentations at AAPM, please visit http://www.viewray.com/aapm_2017.
About ViewRayViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® and MRIdian Linac radiation therapy systems. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the benefits of the MRIdian System. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the MRIdian Linac, competition in the industry in which ViewRay operates and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward- looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
View original content:http://www.prnewswire.com/news-releases/early-clinical-experience-with-viewrays-mridian-linac-presented-at-leading-medical-physics-meeting-300499060.html
SOURCE ViewRay, Inc.
Subscribe to our Free Newsletters!
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...
Palliative care is a specialized multifaceted care for patients with chronic or terminal illness to ...View All